These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16817668)

  • 1. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.
    Cox D; Stone J
    J Neurosci Nurs; 2006 Jun; 38(3):167-71. PubMed ID: 16817668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications.
    Mohr DC; Cox D; Epstein L; Boudewyn A
    J Behav Ther Exp Psychiatry; 2002 Mar; 33(1):39-47. PubMed ID: 12389798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
    Fraser C; Hadjimichael O; Vollmer T
    J Neurosci Nurs; 2001 Oct; 33(5):231-9. PubMed ID: 11668881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data.
    Caon C; Saunders C; Smrtka J; Baxter N; Shoemaker J
    J Neurosci Nurs; 2010 Oct; 42(5 Suppl):S5-9. PubMed ID: 21049828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis.
    Lesaux J; Jadbäck G; Harraghy CE
    J Neurosci Nurs; 1999 Jun; 31(3):174-9. PubMed ID: 10846648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.
    Mohr DC; Boudewyn AC; Likosky W; Levine E; Goodkin DE
    Ann Behav Med; 2001; 23(2):125-32. PubMed ID: 11394554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program].
    Visy JM; Gentin M; Bazerque C;
    Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
    Lugaresi A; De Robertis F; Clerico M; Brescia Morra V; Centonze D; Borghesan S; Maniscalco GT;
    Expert Opin Drug Deliv; 2016 Jul; 13(7):931-5. PubMed ID: 26909646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimized compliance].
    Krankenpfl J; 2005; 43(7-10):238. PubMed ID: 16515308
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferons: a nurses' review of a novel multiple sclerosis therapy.
    Howley A; Kremenchutzky M
    J Neurosci Nurs; 2014 Apr; 46(2):88-96. PubMed ID: 24556656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments.
    Al-Hussain F; Al-Salloum N; Alazwary N; Saeedi J; Howaidi S; Daif A
    J Comp Eff Res; 2017 Jul; 6(5):405-412. PubMed ID: 28699780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
    Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
    Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging oral therapies for multiple sclerosis.
    Cohen BA; Rieckmann P
    Int J Clin Pract; 2007 Nov; 61(11):1922-30. PubMed ID: 17784852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Ingwersen J; Aktas O; Hartung HP
    Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.